Amarantus Bioscience Holdings Inc (AMBS)

[MagicCap]

I'm not sure when the transfer will occur but I do think that will cause a temporary drop. The drops are becoming shallower and shallower and the rebounds are coming much quicker. I think this will be the last opportunity for anyone looking to get in. I have no idea what the drop would go down to but the two levels I'm watching to add are $0.10 and $0.087.

Either way, AMBS is an EPIC Stock. EPIC Stocks can be found once every 5 years or so. They go up 100 to 300 times their value over the span of 6 to 12 months. Bashers come on board and try to knock it down only to watch it put in higher lows throughout the run and leave people without patience sitting in awe as the stock barrels higher. People will try to spin wild webs of fancy like dilution, conspiracy theories as to why they drop suddenly every once in a while, etc. Yet after each minor blip it continues higher. Anyone that sells is left kicking themselves. That's what EPIC stocks do.

There are far too many positives here and the valuation is still ridiculously low. Here is a list of just some of the positives (First few are showing the ties amongst the other trophic factors, CDNF and GDNF and Neurturin and how it proves that the value of MANF is multiples higher than $30 Million which is what AMBS's market cap is):


(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family

(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants

(3) World renown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board

(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins

(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html

(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s

(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.

(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.

(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.

(10) World renown Joseph Rubinfeld, co-founder of Amgen, has stated that MANF could be the biggest success he has ever seen and that if AMBS pursues an Orphan Drug strategy it could be a blockbuster drug.